UNSPSC 51112503: Bendamustine

This classification denotes a nitrogen mustard compound with the molecular formula C16H21Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9266D9P3PQ, chemically known as 2-benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride but more generally known as bendamustine, which bears US NIH Compound Identifier 65628. Bendamustine most often comes in base and hydrochloride forms.

UNSPSC 51112503 Bendamustine is a Commodity code covering a chemotherapy agent actively procured by state and local health systems, correctional departments, and public hospital networks for oncology and hematology treatment programs. Bendamustine is a nitrogen mustard alkylating agent used primarily to treat chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and related malignancies in state-run and county-operated medical facilities. State and local issuing bodies source bendamustine through direct purchase orders, standing supply agreements with pharmaceutical vendors, and cooperative purchasing vehicles such as state health department formularies and correctional health care consortia. The procurement typically involves bulk or unit-dose formulations supplied to centralized pharmacy distribution centers, regional medical centers, or individual correctional facilities within a health system.

The source provided contains no recent state and local contract opportunities under this code and does not supply information on geographic concentration, issuing-body frequency, or representative solicitations.